• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - Respiratory
Tag:

Respiratory

Health

Scientists map 239 human-infective RNA viruses to track future outbreak risks

by Chief Editor April 27, 2026
written by Chief Editor

The Hidden Map of Viral Threats: Decoding the RNA Landscape

The battle against emerging infectious diseases is often a race against an invisible enemy. A comprehensive new global dataset has recently brought the number of known human-infective RNA virus species to 239. This isn’t just a list; it is a roadmap showing how animal hosts, transmission routes, and surveillance gaps dictate whether a virus remains a rare occurrence or becomes a global crisis.

While the number of recognized species has grown—increasing by 25 since 2018—the data reveals a striking pattern. Most of these viruses are not random anomalies; they cluster within a few specific families and are heavily linked to non-human hosts, particularly mammals.

Did you know? The first human RNA virus ever reported was the Yellow fever virus back in 1901. Since then, discovery rates peaked significantly in the 1960s and again in the early 2000s.

Why Mammals are the Primary Bridge

The data underscores a critical biological reality: mammals are the central players in viral emergence. Most human-infective RNA viruses are associated with non-human mammalian hosts, creating a natural bridge for “spillover” events.

Why Mammals are the Primary Bridge
Level Vector Why Mammals

However, spillover does not automatically lead to a pandemic. The research highlights a critical bottleneck between the initial exposure and sustained human-to-human spread. While many viruses can jump from an animal to a human, only a slight fraction possess the traits necessary to adapt and thrive within human populations.

The Bottleneck: From Spillover to Epidemic Potential

Not all viruses are created equal. Scientists now classify transmissibility into levels to better predict risk. According to the latest findings, 62% of these RNA viruses are strictly zoonotic (Level 2), meaning they can infect a human but cannot spread to another person.

In contrast, only 60 species have reached Level 4, meaning they are either endemic in humans or capable of causing epidemic spread. Even among these high-risk viruses, many still maintain animal reservoirs, making them persistent threats that cannot be easily eradicated.

The Dominance of Vector-Borne Spread

When looking at how these pathogens move, vector-borne transmission—primarily via ticks and mosquitoes—is the dominant route. Here’s followed by inhalation and direct contact pathways.

View this post on Instagram about Vector, The Dominance of Vector
From Instagram — related to Vector, The Dominance of Vector

Recent events involving the Oropouche virus and SARS-CoV-2 serve as stark reminders of how quickly these pathways can lead to widespread outbreaks. The diversity of these routes means that surveillance cannot focus on a single method of transmission if we hope to catch the next threat early.

Pro Tip: To understand the broader context of these threats, explore how metagenomics is used to identify viruses that don’t fit traditional profiles.

Predicting the Next Outbreak: The Future of Surveillance

The future of global health security is shifting from broad, reactive searches to targeted, proactive surveillance. Instead of searching blindly for any new pathogen, experts are now using datasets to pinpoint “high-risk” zones.

Chapter 25 – The RNA Viruses that Infect Humans

Targeting the “Dark Matter” of the Virosphere

The integration of artificial intelligence is revolutionizing discovery. For example, deep learning algorithms like LucaProt are now being used to identify highly divergent RNA viral “dark matter” by integrating sequence and predicted structural information. This allows scientists to find viruses that were previously invisible to standard detection methods.

By focusing on high-risk viral families and mammalian reservoirs in regions where surveillance is currently weak, health organizations can identify undetected spillovers before they evolve into epidemics.

The Role of Real-Time Genomic Sequencing

Closing the knowledge gaps around transmission routes and host ranges requires a commitment to real-time genomic sequencing. When we can map a virus’s genome the moment it emerges, we can determine its “Level” of transmissibility much faster, allowing for more precise public health interventions.

The Role of Real-Time Genomic Sequencing
Level Vector

For more detailed insights on viral classification, you can refer to the full catalogue in Scientific Data.

Frequently Asked Questions

How many RNA viruses are known to infect humans?
As of the complete of 2024, there are 239 recognized species of human-infective RNA viruses.

What is a “zoonotic” virus?
A zoonotic virus is one that is transmitted from animals to humans. Most human RNA viruses (62%) are strictly zoonotic and do not spread from human to human.

Which transmission route is most common for these viruses?
Vector-borne transmission, specifically through mosquitoes and ticks, is the most dominant route of spread.

Why are RNA viruses considered a greater threat than others?
Their ability to rapidly change, their diverse host ranges (especially in mammals), and their potential for epidemic spread—as seen with influenza and SARS-CoV-2—make them a primary focus for public health.

Stay Ahead of the Curve

Do you think AI will eventually allow us to predict a pandemic before the first human case occurs? Share your thoughts in the comments below or subscribe to our newsletter for the latest updates in viral research and global health.

April 27, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Air quality in infancy may fundamentally shape long-term immune development

by Chief Editor April 24, 2026
written by Chief Editor

Beyond the Lungs: How Urban Air Pollution Shapes Infant Immune Resilience

For years, the medical community has understood the dangers of tobacco smoke on developing lungs. However, emerging research is revealing a more complex story: the very air infants breathe in urban environments may fundamentally alter their immune systems before they even reach their first birthday.

Beyond the Lungs: How Urban Air Pollution Shapes Infant Immune Resilience
Rome Immune Precision

Preliminary findings from the Immune Development in Early Life (IDEaL) Rome Cohort suggest that ambient air pollution does more than irritate the respiratory tract—it may disrupt immune maturation during critical developmental windows, leaving infants more vulnerable to a variety of infections.

Did you understand? Research indicates a significant positive correlation between particulate matter (PM₁₀) and recurrent respiratory infections, with a correlation coefficient of r=0.47.

The Invisible Threat: Urban Pollutants and the Developing Immune System

The impact of urban living on pediatric health is becoming increasingly clear. Data from the IDEaL Rome cohort, a longitudinal study supported by the NIH and NIAID and led by the Precision Vaccines Program at Boston Children’s Hospital, highlights a clear link between common urban pollutants and respiratory burden.

View this post on Instagram about Rome, Immune
From Instagram — related to Rome, Immune

According to Donato Amodio, MD, PhD, Assistant Professor at Ospedale Pediatrico Bambino Gesù (OPBG), these environmental exposures may “fundamentally shape” an infant’s immune resilience. This suggests that the vulnerability to infection is not just about the lungs, but about how the immune system learns to respond to threats.

Which Pollutants Pose the Greatest Risk?

The study identified three primary culprits in urban air that correlate with higher infection rates in the first year of life:

  • Particulate Matter (PM₁₀): Showed the strongest correlation with total recurrent respiratory infections (r=0.47).
  • Nitrogen Oxides (NOₓ): Significantly linked to infection burden (r=0.39).
  • Nitrogen Dioxide (NO₂): Also demonstrated a significant positive correlation (r=0.39).

These pollutants are not only tied to general recurrent respiratory infections (RRI) but also to specific episodes of wheezing, with PM₁₀ showing a correlation of r=0.25.

The Ripple Effect: From Bronchiolitis to SARS-CoV-2

The burden of air pollution isn’t limited to a single type of illness. The IDEaL Rome research found that various individual infections demonstrated significant, though more modest, effects (averaging r~0.20). These include:

Introduction To Air Quality
  • Bronchiolitis and bronchitis
  • Acute otitis media (middle ear infections)
  • Tonsillitis
  • SARS-CoV-2 infection

This broad spectrum of infections suggests that airborne pollutants may act as systemic disruptors, weakening the body’s overall ability to fight off diverse respiratory pathogens.

Pro Tip: To better understand the risks in your area, look for local government air quality monitoring stations that track PM₁₀ and NO₂ levels, as these are key indicators of potential respiratory risks for infants.

Future Trends: High-Resolution Monitoring and Precision Protection

The next frontier in pediatric environmental health is the shift toward high-resolution environmental monitoring. By integrating more precise data, researchers aim to refine exposure estimates and clarify the exact mechanisms that link pollutants to impaired immune defenses.

Future Trends: High-Resolution Monitoring and Precision Protection
Rome Immune Precision

This evolution in data collection could lead to a latest era of “precision protection,” where environmental health interventions are tailored to the most critical developmental windows of infancy. The goal is to reduce infection vulnerability by safeguarding the air quality during the first twelve months of life.

As the Pediatric Academic Societies (PAS) continue to present findings on these immunologic pathways, the urgency for stronger environmental protections to safeguard children’s early development becomes increasingly evident.

Frequently Asked Questions

What is the IDEaL Rome Cohort?
We see part of a longitudinal study led by the Precision Vaccines Program at Boston Children’s Hospital and supported by the NIH/NIAID, investigating risk factors and immunologic pathways that contribute to infection vulnerability and asthma in early life.

How does air pollution affect an infant’s immune system?
Airborne pollutants are recognized as potential disruptors of immune maturation during critical developmental windows, which may reduce immune resilience and increase the burden of respiratory infections and wheezing.

Which specific infections are linked to air pollution in infants?
Research shows correlations with recurrent respiratory infections, wheezing, bronchiolitis, bronchitis, acute otitis media, tonsillitis, and SARS-CoV-2 infection.

Want to stay informed on the latest in pediatric health and environmental science?

Explore our related articles on respiratory health and infant immune development, or subscribe to our newsletter for expert insights delivered to your inbox.

Do you live in a high-pollution urban area? Share your experiences or questions in the comments below.

April 24, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Study finds long COVID leaves a distinct immune signature in the blood

by Chief Editor April 15, 2026
written by Chief Editor

Unlocking Long COVID: New Protein Patterns Offer Hope for Diagnosis and Treatment

Recent research is shedding light on the complex biological mechanisms behind Long COVID, identifying distinct protein patterns in the blood that differentiate those still struggling with symptoms months after infection from those who have recovered. A study published in Communications Medicine reveals key inflammatory and neurological markers, offering potential avenues for improved diagnosis and targeted therapies.

The Persistent Puzzle of Long COVID

An estimated 5% to 30% of individuals infected with SARS-CoV-2 experience symptoms lasting months, a condition known as Long COVID. The core question remains: why do some fully recover while others face debilitating fatigue, brain fog, and chronic inflammation? Researchers are increasingly focused on immune dysregulation as a key factor, but identifying reliable biomarkers has proven challenging.

Key Protein Signatures Identified

The study, conducted on participants in Australia, compared blood samples from healthy individuals, those who had recovered from COVID-19, and individuals experiencing Long COVID. Researchers measured 182 inflammatory and neurology-related proteins, pinpointing several that stood out. Elevated levels of interleukin-20 (IL-20), macrophage chemoattractant protein-1 (MCP-1), and neuroblastoma suppressor of tumorigenicity 1 (NBL1) were particularly prominent in individuals with Long COVID, suggesting ongoing inflammation.

Interestingly, even those who had recovered from the initial infection showed some lingering protein differences compared to healthy controls, with fibroblast growth factor 19 (FGF-19) and cystatin D (CST5) associated with recovery status. This suggests that immune alterations can persist even after clinical recovery.

Pro Tip: Understanding these protein signatures could lead to the development of diagnostic tests to identify individuals at risk of developing Long COVID early on, allowing for proactive intervention.

Vaccination and Reinfection: A Shifting Immune Landscape

The research also investigated how vaccination and reinfection impact these protein patterns. Booster doses prompted strong antibody responses in all groups, but individuals with Long COVID and those who had previously recovered exhibited lower spike-specific antibody levels after breakthrough infections compared to those newly infected.

Crucially, the study found that the inflammatory patterns observed after the initial infection were not replicated following reinfection in individuals with Long COVID. This suggests the immune system reacts differently upon subsequent exposure to the virus.

Perhaps most reassuringly, vaccination did not worsen inflammation in individuals with Long COVID. in fact, inflammatory protein levels either stabilized or decreased. This reinforces the importance of vaccination, even for those experiencing long-term symptoms.

Implications for Future Research and Treatment

These findings represent a significant step forward in unraveling the complexities of Long COVID. Identifying these distinct immune alterations opens doors for developing targeted therapies aimed at modulating the immune response and alleviating symptoms. Further research is needed to validate these findings in larger cohorts and explore the potential of these protein markers as diagnostic tools.

The Role of Persistent Viral Presence

Emerging research suggests that the persistence of SARS-CoV-2 RNA or particles in tissues may play a role in driving the chronic inflammation seen in Long COVID. While the exact mechanisms are still being investigated, this persistent viral presence could be triggering ongoing immune dysregulation.

FAQ: Long COVID and Immune Response

Q: What is Long COVID?
A: Long COVID refers to symptoms that persist for weeks or months after the initial SARS-CoV-2 infection.

Q: Are vaccinations safe for people with Long COVID?
A: This study suggests vaccinations are well-tolerated and do not worsen inflammation in individuals with Long COVID.

Q: What are the key symptoms of Long COVID?
A: Common symptoms include fatigue, brain fog, and chronic inflammation.

Q: Can reinfection with SARS-CoV-2 worsen Long COVID?
A: The immune response to reinfection appears different than the initial infection, but this study did not find evidence of worsened inflammation.

Did you know? The number of symptoms associated with Long COVID exceeds 200, highlighting the diverse and individualized nature of the condition.

Wish to learn more about the latest research on Long COVID? Visit the CDC’s Long COVID page for up-to-date information and resources.

Share your experiences with Long COVID in the comments below. What symptoms have you experienced, and how has vaccination impacted your recovery?

April 15, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Study explains why vaccines underperform in people living with obesity

by Chief Editor April 13, 2026
written by Chief Editor

Obesity’s Impact on Vaccine Effectiveness: A Shift Towards Tissue-Specific Immunity

For years, vaccine development has largely focused on stimulating a robust antibody response. However, emerging research suggests this approach may be less effective in individuals with obesity. A recent study published in The Journal of Immunology reveals that obesity significantly impairs the quality and longevity of antibody responses to a Pseudomonas aeruginosa vaccine in a mouse model. This isn’t simply a matter of reduced antibody levels; the very structures within the immune system responsible for producing those antibodies – germinal centers – are compromised.

The Germinal Center Dilemma

Germinal centers are crucial for the development of long-lasting immunity. They are where B cells, the immune cells that create antibodies, mature and refine their ability to target pathogens. The study found that defects within these germinal centers in obese mice led to diminished antibody production. This finding offers a key insight into why traditional vaccines often underperform in people with obesity, a population already at higher risk for severe respiratory infections.

A Silver Lining: The Power of Tissue-Resident Memory T Cells

Despite the weakened antibody response, the research uncovered a surprising protective mechanism. The P. Aeruginosa vaccine triggered a strong response from lung tissue-resident memory T cells. Unlike circulating T cells, these specialized cells permanently reside in the lungs, providing a first line of defense directly at the site of infection. This early protection wasn’t observed in mice with a normal or low-fat diet, suggesting these resident memory T cells were compensating for the antibody deficiencies.

Pro Tip: Tissue-resident memory T cells are increasingly recognized as critical for rapid immune responses in barrier tissues like the lungs, skin, and gut.

Redefining Vaccine Strategy: Prioritizing Local Immunity

These findings are prompting a re-evaluation of vaccine design. Dr. Wendy L. Picking, lead author of the study, emphasizes the need to move beyond simply boosting blood antibody levels. “Instead of just trying to boost blood antibody levels, we should intentionally design vaccines that prioritize tissue-resident immunity, ensuring protection directly where pathogens like Pseudomonas enter the body,” she stated.

Why This Matters: Pseudomonas aeruginosa and Antibiotic Resistance

Pseudomonas aeruginosa is a particularly concerning pathogen, being a leading cause of severe pneumonia, especially in individuals with obesity. Adding to the challenge, the bacteria is increasingly exhibiting antibiotic resistance, making infections harder to treat. Effective vaccines are therefore crucial, and understanding how obesity impacts immune responses is a critical step forward.

Did you know? No other studies have previously examined the effectiveness of vaccines targeting gram-negative bacterial pathogens, like P. Aeruginosa, in the context of obesity.

Future Directions: Unlocking the Secrets of Tissue-Resident Immunity

Researchers are now focused on identifying the specific molecular signals that allow lung tissue-resident memory T cells to grow activated despite the chronic inflammation often associated with obesity. Optimizing vaccine formulations to further enhance these resident memory cells is the ultimate goal. The aim is to create vaccines that provide robust protection for everyone, regardless of metabolic health.

FAQ

Q: Does obesity completely negate the effectiveness of vaccines?
A: No, the study shows vaccines can still generate a protective response, particularly through tissue-resident memory T cells. However, the antibody response is diminished, potentially reducing overall protection.

Q: What is a tissue-resident memory T cell?
A: These are specialized immune cells that live permanently in tissues like the lungs, providing rapid, localized protection against infection.

Q: Is this research applicable to other vaccines besides the Pseudomonas aeruginosa vaccine?
A: Whereas this study focused on P. Aeruginosa, the principles of impaired germinal center function and the importance of tissue-resident immunity may apply to other vaccines as well.

Q: What can individuals with obesity do to improve their vaccine response?
A: Maintaining a healthy lifestyle, including a balanced diet and regular exercise, can help reduce chronic inflammation and potentially improve immune function. Consult with your healthcare provider for personalized advice.

Want to learn more about the latest advancements in immunology and vaccine development? Explore our other articles on News-Medical.net and stay informed about the evolving landscape of infectious disease prevention.

April 13, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Lab study shows cigarette smoke damaged lung cells more than e-cigarette vapor

by Chief Editor April 13, 2026
written by Chief Editor

Cigarette Smoke vs. E-Cigarettes: Latest Research Reveals Stark Differences in Lung Cell Damage

A groundbreaking laboratory study published in Scientific Reports has revealed significant differences in how cigarette smoke and e-cigarette vapor affect human lung cells. Researchers at the University of Graz, Austria, found that cigarette smoke extract (CSE) caused substantial disruption to lung cell barriers, triggered inflammation, and damaged DNA, while e-cigarette vapor extract (EVE) showed no significant adverse effects under the same experimental conditions.

The Vulnerable Lung Barrier

Our airway epithelium acts as a crucial defense mechanism, protecting the body from inhaled particles and harmful substances. Cigarette smoke is well-established as a damaging agent to this barrier, contributing to conditions like chronic obstructive pulmonary disease (COPD). The question of whether e-cigarettes pose a similar threat has remained a subject of debate.

View this post on Instagram

This study utilized human Calu-3 lung epithelial cells, meticulously cultured and exposed to CSE and EVE. Researchers assessed barrier integrity, inflammation levels, and DNA damage using a range of sophisticated techniques, including Transwell systems, Western blotting, and DNA strand break assays.

CSE’s Damaging Effects: A Cascade of Cellular Disruption

The results were striking. CSE significantly reduced the electrical resistance of the cell barrier, indicating compromised cell cohesion and increased permeability. So harmful substances could more easily penetrate the lung tissue. CSE decreased the expression of key proteins – claudin-1 and occludin – essential for maintaining the integrity of the apical junctional complex, a critical component of the epithelial barrier. A 45% decline in claudin-1 levels was observed, highlighting its vulnerability to smoke exposure.

Inflammation also surged in cells exposed to CSE, with interleukin-6 (IL-6) levels increasing up to tenfold. Significant DNA damage, indicated by increased DNA strand breaks, was also detected. Notably, the study suggests that the damage caused by cigarette smoke isn’t solely attributable to nicotine, implying other toxic components are at play.

EVE: A Different Story

In stark contrast, EVE did not significantly impact barrier integrity, inflammation, or DNA damage. In some instances, it even appeared to slightly improve barrier stability. This suggests that, under the conditions tested in this in vitro model, e-cigarette vapor exerts less harmful effects on lung epithelial cells compared to cigarette smoke.

What Does This Imply for Public Health?

These findings offer valuable insights into the differing impacts of cigarette smoke and e-cigarette vapor on lung health. While CSE demonstrably disrupts cellular defenses, EVE did not exhibit the same detrimental effects. Though, researchers emphasize that this study was conducted in vitro, meaning in a laboratory setting, and doesn’t directly translate to human health outcomes.

The study used unflavored e-liquid, and the authors acknowledge that the use of liquid extracts rather than direct aerosol exposure may limit the generalizability of the findings. Further research, utilizing more representative biological systems, is crucial to fully understand the long-term health effects of e-cigarette vapor.

Pro Tip: Maintaining a healthy lung barrier is vital for overall respiratory health. Avoiding smoke exposure, whether from cigarettes or other sources, is a key step in protecting your lungs.

Future Trends in Respiratory Research

This study underscores a growing trend in respiratory research: the use of advanced in vitro models, like the Calu-3 cell system, to investigate the effects of inhaled substances. Expect to see more research focusing on:

  • Flavoring Chemicals: The impact of various e-liquid flavoring chemicals on lung cells is an area of increasing concern. Studies are beginning to assess the toxicity of cinnamon, vanilla tobacco, and hazelnut flavors.
  • Long-Term Exposure: Most studies to date have focused on short-term exposure. Longitudinal studies are needed to understand the cumulative effects of e-cigarette vapor over years or decades.
  • Individual Variability: Responses to inhaled substances can vary significantly between individuals. Research is exploring how genetic factors and pre-existing conditions influence susceptibility to lung damage.
  • Air-Liquid Interface (ALI) Models: Utilizing ALI models, which more closely mimic the lung environment, will provide more accurate and relevant data.

FAQ

Q: Does this study mean e-cigarettes are safe?
A: No. This study shows that, under the tested conditions, e-cigarette vapor appeared less harmful than cigarette smoke to lung cells. However, it does not prove e-cigarettes are entirely safe, and long-term effects remain unknown.

Q: What is the Calu-3 cell line?
A: Calu-3 is a human lung adenocarcinoma epithelial cell line commonly used in respiratory research to model lung function and responses to inhaled substances.

Q: What is the apical junctional complex?
A: The apical junctional complex is a protein network that forms a seal between lung epithelial cells, maintaining barrier integrity and preventing harmful substances from entering the body.

Q: What is IL-6?
A: IL-6 is an interleukin, a type of signaling molecule involved in inflammation. Elevated IL-6 levels indicate an inflammatory response.

Want to learn more about lung health and respiratory diseases? Explore our extensive library of articles on News-Medical.net.

April 13, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Study identifies four radiomic profiles linked to sarcoidosis severity

by Chief Editor April 10, 2026
written by Chief Editor

Revolutionizing Sarcoidosis Diagnosis: How AI-Powered CT Scans Are Changing the Game

For the over 150,000 Americans living with sarcoidosis, a complex inflammatory lung disease, diagnosis and monitoring have long been a challenge. Traditional methods rely on visual assessment of chest CT scans, a process prone to variability between specialists. But a recent era in sarcoidosis care is dawning, powered by radiomics – a cutting-edge technology that uses artificial intelligence to unlock hidden insights within these scans.

What is Radiomics and Why Does It Matter?

Radiomics isn’t about replacing radiologists; it’s about augmenting their expertise. This computer-based imaging technique employs advanced algorithms to measure hundreds of quantitative features from medical images, far beyond what the human eye can discern. These features capture subtle patterns in lung tissue, providing a multidimensional characterization of the disease.

View this post on Instagram

“We found that radiomic analysis of CT scans can reveal distinct patterns of lung abnormalities in sarcoidosis,” explains Tasha Fingerlin, PhD, of National Jewish Health. “These patterns were associated with differences in lung function, suggesting that this approach may help us better understand how the disease varies from patient to patient.”

Four Distinct Profiles: Unlocking Sarcoidosis Subtypes

Researchers at National Jewish Health, analyzing CT scans from 320 sarcoidosis patients as part of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) Study, have identified four distinct imaging profiles. These profiles range from patients with minimal lung abnormalities to those exhibiting patterns indicative of significant inflammation or fibrosis. Crucially, these radiomic groups correlated with differences in lung function, even after accounting for traditional imaging assessments.

This discovery is significant because current staging systems, while helpful, don’t always capture the full complexity of the disease. Radiomics offers a more detailed and reproducible way to quantify these patterns.

Beyond Diagnosis: Tracking Disease Progression and Personalizing Treatment

The potential of radiomics extends far beyond initial diagnosis. Because the analysis can be performed quickly and automatically using open-source software, it could enable clinicians to analyze large numbers of scans and track disease patterns over time with unprecedented efficiency.

“Radiomics has the potential to complement the expertise of radiologists by providing objective measurements of lung abnormalities, identifying disease subtypes, monitoring progression and potentially guiding more personalized treatment strategies,” says Dr. Fingerlin.

Lisa Maier, MD, adds that this technology could be particularly impactful in areas lacking specialized sarcoidosis expertise. “There is promise for significant impact on patient care, especially in regions where there is no expert in sarcoidosis radiology… Radiomics could also expedite care in clinics with rapid turnaround for patients at specialized centers and revolutionize the way we interpret CT scans for research and clinical trials.”

The Future of AI in Pulmonary Imaging

The development of radiomic profiling represents a broader trend: the increasing integration of AI into pulmonary imaging. Expect to observe further advancements in this field, including:

  • Predictive Modeling: AI algorithms could predict which patients are most likely to experience disease progression or respond to specific treatments.
  • Automated Reporting: AI-powered tools could generate preliminary reports for radiologists, streamlining the workflow and reducing the risk of errors.
  • Integration with Other Data Sources: Combining radiomic data with genomic information, patient history, and other clinical data could provide a holistic view of the disease.

FAQ

What is sarcoidosis? Sarcoidosis is a complex inflammatory lung disease that affects more than 150,000 people in the United States.

What is radiomics? Radiomics is a computer-based imaging technique that analyzes subtle patterns in medical images using advanced algorithms.

How does radiomics improve sarcoidosis diagnosis? Radiomics provides a more objective and reproducible way to assess lung abnormalities, identifying distinct patterns linked to disease severity and lung function.

Is radiomics widely available? While still an emerging technology, radiomics is becoming increasingly accessible thanks to open-source software and growing research efforts.

Will AI replace radiologists? No, radiomics is designed to augment the expertise of radiologists, not replace them.

Did you know? National Jewish Health is a WASOG (World Association of Sarcoidosis and Granulomatous Disease) Center of Excellence for Sarcoidosis, a designation it has held since 2017.

Pro Tip: Early and accurate diagnosis is crucial for effective sarcoidosis management. Discuss the potential benefits of radiomic analysis with your healthcare provider.

Want to learn more about the latest advancements in lung disease research? Explore our other articles on pulmonary health and innovative diagnostic techniques.

April 10, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Machine learning model can predict 28-day mortality in sepsis patients

by Chief Editor March 27, 2026
written by Chief Editor

AI-Powered Precision in Sepsis Care: A Modern Era of Early Risk Prediction

Sepsis, a life-threatening condition arising from the body’s overwhelming response to an infection, remains a major challenge in intensive care units (ICUs). The development of acute respiratory failure (ARF) as a complication significantly increases the risk of death. But, a new machine learning model is offering a beacon of hope, promising more accurate and timely risk assessment for these critically ill patients.

The Challenge of Early Sepsis Prognosis

Despite advancements in critical care, predicting which sepsis patients will succumb to the illness within the first 28 days has been notoriously difficult. Early and accurate assessment is crucial for optimizing treatment strategies and allocating limited ICU resources effectively. Currently, clinicians rely on a combination of clinical judgment and established scoring systems, but these often fall short in providing a precise prognosis.

A New Model for Predicting 28-Day Mortality

Researchers, led by Dr. Jian Liu, have developed and validated a machine learning model specifically designed to predict 28-day mortality in sepsis patients experiencing ARF. The model leverages routinely collected clinical data from the first 24 hours of ICU admission. This focus on readily available information is a key strength, making the model practical for widespread implementation.

The research team trained the model using the Medical Information Mart for Intensive Care IV (MIMIC-IV) database and rigorously tested its performance on an independent dataset, the eICU Collaborative Research Database (eICU-CRD). This ‘training plus external validation’ approach strengthens the model’s reliability and generalizability across diverse patient populations and hospital settings.

XGBoost: The Algorithm of Choice

Among several machine learning algorithms evaluated – including logistic regression, random forests, and neural networks – XGBoost consistently outperformed the others in predicting mortality risk. Importantly, the researchers prioritized interpretability, utilizing SHapley Additive exPlanations (SHAP) to understand which clinical variables were driving the model’s predictions.

This interpretability is a significant departure from many “black box” AI models. By identifying key predictors like oxygenation indices, serum albumin levels, liver function indicators, and disease severity scores, the model provides clinicians with valuable insights into the factors influencing a patient’s prognosis.

Key Clinical Predictors Identified by the Model

The SHAP analysis revealed the critical role of several clinical factors in predicting 28-day mortality. These include:

  • Oxygenation Indices: Reflecting the patient’s ability to effectively exchange oxygen.
  • Serum Albumin Levels: Indicating nutritional status and overall health.
  • Liver Function Indicators: Signaling potential organ dysfunction.
  • Disease Severity Scores: Providing a comprehensive assessment of the patient’s illness.

This transparent framework allows clinicians to understand why the model is making a particular prediction, fostering trust and facilitating informed decision-making.

Future Trends: Integrating AI into Critical Care

This study represents a significant step towards integrating interpretable AI into routine clinical practice. The potential applications extend beyond simply predicting mortality risk.

Personalized Treatment Strategies

By identifying high-risk patients early, clinicians can tailor treatment strategies to individual needs. This could involve more aggressive interventions, closer monitoring, or proactive management of specific organ dysfunction.

Resource Allocation Optimization

In resource-constrained environments, the model can help prioritize care for patients at the highest risk of deterioration, ensuring that limited ICU beds and staff are allocated effectively.

Bedside and Web-Based Risk Assessment Tools

The research team envisions integrating the model into user-friendly tools accessible at the bedside or via web-based platforms, providing clinicians with real-time risk assessments.

Expanding the Scope of AI in Sepsis Management

This work builds on a growing body of research exploring the leverage of AI in sepsis management. Other areas of investigation include:

  • Early Sepsis Detection: Developing models to identify sepsis at its earliest stages, even before symptoms become apparent.
  • Antibiotic Stewardship: Optimizing antibiotic use to combat antimicrobial resistance.
  • Predictive Modeling for ARDS Development: Identifying patients at high risk of developing ARF, allowing for preventative measures.

FAQ

Q: What is sepsis-induced ARF?
A: Sepsis-induced acute respiratory failure (ARF) occurs when sepsis leads to a sudden and severe inability of the lungs to provide enough oxygen to the body.

Q: What is XGBoost?
A: XGBoost is a machine learning algorithm known for its accuracy and efficiency in handling complex datasets.

Q: How does SHAP analysis work?
A: SHAP (SHapley Additive exPlanations) is a method used to explain the output of machine learning models by quantifying the contribution of each feature to the prediction.

Q: Is this model ready for use in hospitals?
A: The model has been externally validated, but further implementation and integration into clinical workflows are needed before widespread adoption.

Did you grasp? Approximately 25-50% of sepsis patients develop acute respiratory distress syndrome (ARDS), significantly increasing their risk of mortality.

Pro Tip: Early identification of sepsis and ARF is critical. Clinicians should be vigilant for signs of these conditions and initiate prompt treatment.

This research marks a pivotal moment in the fight against sepsis. By harnessing the power of machine learning and prioritizing interpretability, we are moving closer to a future where AI empowers clinicians to deliver more precise, personalized, and effective care to the most vulnerable patients.

Explore further: Read more about the study on News Medical and learn about interpretable machine learning.

March 27, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

CDC tracks SARS-CoV-2 BA.3.2 global rise and finds early signals in U.S. wastewater

by Chief Editor March 26, 2026
written by Chief Editor

Fresh COVID Variant “Cicada” (BA.3.2) Spreads: What You Need to Know

Health officials are closely monitoring a newly emerging COVID-19 variant, BA.3.2, nicknamed “Cicada” due to its prolonged period of undetected circulation. The Centers for Disease Control and Prevention (CDC) recently published a report detailing its spread across the globe and within the United States.

Early Detection Through Advanced Surveillance

The CDC’s report highlights the effectiveness of traveler-based genomic surveillance and wastewater monitoring in detecting BA.3.2 early. The variant was first identified in a respiratory sample from South Africa in November 2024. Since then, it has been reported in 23 countries, with detections increasing since September 2025.

In the U.S., BA.3.2 has been found in nasal swabs from travelers, airplane wastewater, clinical samples from patients, and wastewater samples from 25 states. This multi-pronged approach to surveillance is proving crucial in tracking the virus’s evolution.

Genetic Divergence and Immune Evasion Potential

BA.3.2 is genetically distinct from previous variants, possessing approximately 70-75 substitutions and deletions in the spike protein gene sequence compared to JN.1 and LP.8.1. These changes raise concerns about the variant’s potential to evade immunity from prior infection or vaccination.

The CDC is actively analyzing these mutations to understand their impact on vaccine effectiveness and the severity of illness.

Global Spread and Current Prevalence

Globally, detections of BA.3.2 began to rise in September 2025. By February 11, 2026, the variant had been reported in 23 countries. In some European nations, like Denmark, Germany, and the Netherlands, BA.3.2 accounted for approximately 30% of sequenced cases.

Within the U.S., the prevalence of BA.3.2 among sequenced samples was 0.19% as of February 11, 2026, but has increased to 0.55% by March 12, 2026. The first U.S. Case identified through traveler screening occurred in June 2025, involving a person traveling from the Netherlands.

Sublineages and Ongoing Evolution

Phylogenetic analysis has revealed the emergence of two sublineages, BA.3.2.1 and BA.3.2.2, indicating the virus continues to evolve. Researchers are monitoring these sublineages to assess any changes in transmissibility or immune evasion.

Public Health Response and Future Outlook

While BA.3.2 has demonstrated immune evasion potential, current data does not suggest a more severe illness. All patients identified in the U.S. Have survived. The CDC emphasizes the importance of continued genomic surveillance to track the variant’s spread and inform public health strategies.

Sustained monitoring, combined with studies on vaccine and antiviral effectiveness, will be essential to guide future responses to SARS-CoV-2 variants.

FAQ About BA.3.2

What is the BA.3.2 variant? BA.3.2 is a newly identified SARS-CoV-2 variant with a high number of mutations in the spike protein.

Where was BA.3.2 first detected? It was first detected in South Africa in November 2024.

Is BA.3.2 more dangerous than other variants? Current data does not indicate increased severity, but its immune evasion potential is being closely monitored.

How is the CDC tracking BA.3.2? Through traveler-based genomic surveillance, wastewater monitoring, and national genomic surveillance programs.

Should I be concerned about BA.3.2? It’s key to stay informed and follow public health recommendations, but there is no need for undue alarm at this time.

Did you know? Wastewater surveillance can often detect new variants *before* they are identified in clinical cases, providing an early warning system for public health officials.

Pro Tip: Staying up-to-date with your COVID-19 vaccinations remains the best defense against severe illness, even with the emergence of new variants.

Stay informed about the latest developments in COVID-19 and other public health issues. Read the full CDC report here.

March 26, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Can camel milk improve health? Review highlights benefits but warns against drinking it raw

by Chief Editor March 26, 2026
written by Chief Editor

Camel Milk: From Ancient Remedy to Modern Functional Food – What’s Next?

For centuries, camel milk has been a staple in the diets of communities across arid regions of Africa and Asia, valued not just for sustenance but as well for its perceived medicinal properties. Now, a growing body of scientific research is beginning to validate these traditional beliefs, positioning camel milk as a potential “functional food” with benefits ranging from blood sugar control to improved gut health. Still, a recent review published in Food Science & Nutrition underscores a critical caveat: the safety of consuming raw camel milk.

Unlocking the Nutritional Powerhouse

What sets camel milk apart? Unlike cow’s milk, it contains a distinct protein profile, potentially making it a hypoallergenic alternative for those with dairy sensitivities. Studies suggest it has lower levels of A1 β-casein and β-lactoglobulin, proteins linked to digestive discomfort, and allergies. Camel milk boasts a unique composition of insulin-like proteins, protective exosomes, and antibodies, contributing to its potential therapeutic effects.

Metabolic Health and Type 2 Diabetes

Research indicates promising results in managing Type 2 Diabetes (T2D). A randomized controlled trial found that daily consumption of 500 mL of raw camel milk for three months led to a significant reduction in fasting blood glucose levels in patients with T2D – from 9.89 mmol/L to 6.13 mmol/L. HbA1c levels also saw a notable decrease, dropping from 9.44% to 6.61%.

Neurodevelopmental Benefits and Autism

Beyond metabolic health, studies suggest camel milk may positively impact neurodevelopment. Regular consumption has been linked to improvements in social interaction and language skills in children with autism, potentially due to its antioxidant and anti-inflammatory properties, including reductions in tumor necrosis factor-alpha (TNF-α).

Boosting Immunity and Respiratory Health

Camel milk is rich in lactoferrin, an iron-binding protein with antimicrobial properties. Nutriomics studies have found concentrations ranging from 95 to 250 mg/dL, potentially reducing harmful bacterial loads, including Salmonella species. Research also suggests benefits for respiratory health, with children with asthma experiencing reduced reliance on inhaled corticosteroids and rescue inhalers when incorporating 200 mL of camel milk into their daily diet for two months.

The Raw Milk Risk: A Critical Consideration

Despite the growing evidence of potential benefits, the review strongly cautions against consuming raw camel milk. Testing revealed that 43% of samples tested positive for Salmonella spp., with 31% identified as Salmonella enterica. Outbreaks of brucellosis, linked to Brucella melitensis, have also been associated with raw camel milk consumption. Pasteurization remains essential to mitigate these zoonotic risks.

Future Trends and Research Directions

The future of camel milk as a functional food hinges on several key areas of development:

Standardization and Quality Control

Currently, the camel milk industry lacks standardized production and quality control measures. Establishing clear guidelines for sourcing, processing, and storage will be crucial for ensuring product safety and consistency.

Large-Scale Human Trials

Whereas promising, much of the research relies on smaller studies. Larger, well-designed randomized controlled trials are needed to confirm the observed benefits and determine optimal dosages for various health conditions.

Fermentation and Novel Processing Techniques

Fermented camel milk products, like Dhanaan in Ethiopia, have a long history of traditional apply. Investigating the impact of fermentation on the milk’s nutritional profile and therapeutic properties could unlock new benefits and enhance safety.

Metabolomics and Personalized Nutrition

Utilizing metabolomics – the study of compact molecules – can help bridge the gap between nutritional quality and safety evaluation. This approach could lead to personalized dietary recommendations based on an individual’s metabolic profile and response to camel milk consumption.

FAQ

Q: Is camel milk safe for infants?
A: Research is ongoing. While some studies explore its potential, the review doesn’t definitively state its suitability for infants, and pasteurization is crucial.

Q: What is the difference between camel milk and cow’s milk?
A: Camel milk has a different protein profile, potentially making it more hypoallergenic. It also contains unique bioactive compounds like insulin-like proteins.

Q: Can camel milk cure diabetes?
A: No. However, studies suggest it may help manage blood sugar levels in individuals with Type 2 Diabetes.

Q: Is raw camel milk safe to drink?
A: No. The review highlights significant risks of zoonotic diseases associated with raw camel milk consumption.

Did you grasp? Camel milk can remain fresh for up to 12 days when stored at 2°C, significantly longer than cow’s milk.

Explore more articles on functional foods and nutritional science to stay informed about the latest advancements in health and wellness.

March 26, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

U.S. cigarette smoking falls below 10% for the first time but millions still use tobacco

by Chief Editor March 16, 2026
written by Chief Editor

Cigarette Use Plummets, But Tobacco’s Grip on America Persists

For the first time on record, less than 10% of American adults smoke cigarettes, a landmark achievement in public health. Though, a new analysis of data from the 2023 and 2024 National Health Interview Survey (NHIS) reveals that overall tobacco use remains stubbornly high, with nearly one in five adults still using some form of the substance. This suggests a shift in how Americans consume tobacco, rather than a complete abandonment of it.

The Declining Cigarette and the Rise of Alternatives

The study, published in NEJM Evidence, found that cigarette smoking among adults fell from 10.8% in 2023 to 9.9% in 2024. This decline is a testament to decades of public health campaigns, increased taxes, and restrictions on smoking in public places. Despite this success, 47.7 million adults – 18.8% of the population – currently use at least one tobacco product.

While cigarettes remain the most popular product, the use of cigars, e-cigarettes, and smokeless tobacco is holding steady. Approximately 7.0% of adults use e-cigarettes, 3.7% use cigars, and 2.6% use smokeless tobacco. The inclusion of nicotine pouches in the 2024 smokeless tobacco category makes direct year-over-year comparisons challenging, but the trend is clear: smokers are exploring alternatives.

Who is Still Using Tobacco? A Look at Disparities

Tobacco use isn’t evenly distributed across the population. Significant disparities exist based on gender, age, socioeconomic status, and occupation. Men are significantly more likely to use tobacco than women (24.1% vs. 13.9% in 2024). Young adults aged 18-24 show a preference for e-cigarettes, with 14.8% reporting vaping compared to 3.4% who smoke cigarettes.

Socioeconomic factors also play a crucial role. Adults with a General Educational Development (GED) certificate have a tobacco use rate exceeding 40%, and those with lower incomes are more likely to use tobacco than those with higher incomes. Rural residents (27.0%) also report higher tobacco use than urban residents (17.5%).

Certain occupations also exhibit higher rates of tobacco use. Workers in agriculture, forestry, fishing, mining, hunting, and utilities have a prevalence of 29.4%, while those in construction and manufacturing report rates of approximately 28.6%. Conversely, those in education and healthcare sectors show lower rates of tobacco use.

The Impact of Poly-Tobacco Use

The study also sheds light on the growing trend of poly-tobacco use – using multiple tobacco products simultaneously. While most users (80%) stick to a single product, 17.4% report using two products, 2.3% use three, and 0.3% use all four products assessed. This suggests that some individuals are diversifying their nicotine intake, potentially mitigating the effectiveness of interventions targeting a single product.

Future Trends and Public Health Implications

The continued decline in cigarette smoking is encouraging, but the persistence of overall tobacco use presents ongoing challenges. Several trends are likely to shape the future of tobacco control:

  • The Evolution of Nicotine Products: Expect to see continued innovation in nicotine delivery systems, including new types of e-cigarettes, heated tobacco products, and nicotine pouches.
  • Targeted Interventions: Public health efforts will need to become more targeted, addressing the specific needs of high-risk populations, such as young adults, individuals with lower socioeconomic status, and workers in certain occupations.
  • Regulation of Novel Products: Increased regulation of e-cigarettes and other novel nicotine products will be crucial to prevent youth initiation and ensure product safety.
  • Focus on Cessation: Expanding access to effective cessation programs and resources will be essential to support current tobacco users quit.

Did You Know?

The U.S. Is aiming to reduce adult smoking prevalence to 6.1% by 2030 as part of the Healthy People 2030 initiative. If the current rate of decline continues, this goal may be achievable.

FAQ

  • What is the current cigarette smoking rate in the U.S.? 9.9% of U.S. Adults reported smoking cigarettes in 2024.
  • Is e-cigarette use increasing or decreasing? E-cigarette use remains relatively stable, with approximately 7.0% of adults currently using these products.
  • Which demographic groups have the highest rates of tobacco use? Men, young adults, individuals with lower incomes and education levels, and those working in certain occupations (agriculture, construction, manufacturing) have higher rates of tobacco use.
  • What is poly-tobacco use? Poly-tobacco use refers to the simultaneous use of multiple tobacco products, such as cigarettes and e-cigarettes.

Pro Tip: If you’re looking to quit tobacco, resources are available! The Centers for Disease Control and Prevention (CDC) offers a wealth of information and support.

What are your thoughts on the future of tobacco control? Share your comments below!

March 16, 2026 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Recent Posts

  • King Charles III Urges Western Unity for Ukraine in US Congress Address

    April 29, 2026
  • Kolejna ofiara Ozempicu: Niebezpieczne skutki (WIDEO)

    April 29, 2026
  • Cobolli Stuns Medvedev to Reach Madrid Masters Quarterfinals

    April 29, 2026
  • Nvidia Game Ready Driver 596.36: RTX 5070 Laptop and DLSS 4.5 Support

    April 29, 2026
  • Iran offers crude oil supply to South Africa amid conflict shock

    April 29, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: o f f i c e @byohosting.com


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World